An Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers
Phase of Trial: Phase I
Latest Information Update: 01 Mar 2015
Price : $35 *
At a glance
- Drugs Icatibant (Primary)
- Indications Hereditary angioedema
- Focus Pharmacokinetics
- Sponsors Shire
- 11 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Mar 2014 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.
- 03 Mar 2014 Planned End Date changed from 1 May 2014 to 1 Apr 2014, as per ClinicalTrials.gov record.